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Abstract
Background A high level of endogenous erythropoietin
(EPO) may be associated with a smaller infarct size deter-
mined by the release of necrosis markers. Sleep-disordered
breathing (SDB) is a well-known risk factor for cardiovas-
cular diseases. In contrast, protective effects of SDB have
also been described. The potential role of increased levels of
EPO and vascular endothelial growth factor (VEGF) is
suggested in this process. The study aimed to explore the
EPO and VEGF serum levels in SDB and non-SDB patients
during the acute phase of myocardial infarction.
Methods Thirty-seven patients undergoing successful
primary percutaneous coronary intervention in the acute
myocardial infarction have been examined for the levels
of EPO, VEGF, and troponin I (Tn). In the following,
patients had an overnight polysomnography to determine
breathing disturbances during sleep.
Results Both on admission day (day 1) and day 3 of hospi-
talization, EPO levels showed statistically significant differ-
ences in both SDB-positive and SDB-negative patient
groups (p=0.003 and p=0.018, respectively). There was
no statistically significant difference in VEGF levels. No
correlation was found between the EPO and Tn levels.
Conclusions SDB patients tend to have higher levels of
EPO during acute myocardial infarction. No statistically
significant differences in VEGF levels were observed.
Keywords Erythropoietin . Myocardial infarction .
Polysomnography . Sleep-disordered breathing
Introduction
In response to ischemia, mammalian cells express a variety
of proteins, among which erythropoietin (EPO) plays a
crucial role. EPO has long been identified as a primary
regulator of erythropoiesis in bone marrow. EPO has also
been reported to be expressed in the liver, lung, spleen,
uterus, heart, testes, and neuroglia [1]. Furthermore, over
the last decade EPO has also been recognized to play a role
in a broad variety of processes in cardiovascular pathophys-
iology. In particular, the strong interactions of EPO with the
nitric oxide pathway, apoptosis, ischemia, cell proliferation,
and platelet activation appear to be of great interest for
clinicians.
Serum EPO levels in patients with myocardial infarc-
tion were also investigated. In humans with acute myo-
cardial infarction who had successful reperfusion with
primary or rescue percutaneous coronary intervention
(PCI), clinical trials with intravenous administration of
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EPO analogues did not show to reduce infarct size nor
did it improve left ventricular ejection fraction. Pro-
longed EPO therapy after myocardial infarction (MI) in
a large animal model was shown to be safe and lead to
an increase in viable myocardium, increased vascular
density, and was shown to prevent further deterioration
of left ventricular function [2].
Cell culture models as well as animal models were
used to prove that EPO administration may protect
cardiomyocytes against cell death induced by ischemia
and cytotoxic agents. In details, the antiapoptotic effect
of EPO has been described in rat cardiac myocytes [3]
and myoblasts subjected to hypoxia [4]. It was EPO that
stimulated vascular endothelial growth factor (VEGF)
gene expression.
It is well known that EPO release is highly induced under
hypoxic conditions. For both renal and extra-renal EPO
production, oxygen tension in tissues, not the red blood cell
(RBC) count, primarily determines de novo EPO synthesis.
Nocturnal hypoxemia-reoxygenation cycles that are typical
to sleep-disordered breathing (SDB) may lead to an ische-
mic preconditioning conferring profound protection from
infarction. Apneic episodes during sleep may in conse-
quence promote certain cytokines production and release
to the blood. Among them, EPO and VEGF may be key
players in pre-conditioning mechanisms enabling myocyte
survival.
The purpose of the present study was to investigate
whether sleep apnea patients with acute myocardial infarc-
tion treated with successful PCI had different serum EPO
and VEGF levels when compared to non-SDB patients and
whether it correlated with the size of the infarction deter-
mined by the release of troponin.
Material and methods
Patients
The study enrolled 37 men at ages below 65 years (mean
age, 52.1±6.5 years) admitted to the 1st Department of
Cardiology at Medical University of Warsaw between Feb-
ruary 2006 and December 2007. Acute myocardial infarc-
tion (AMI) was diagnosed according to the universal
definition of myocardial infarction. The eligible patients
were those men with first AMI who received successful
primary PCI for the infarct-related coronary artery within
12 h from the onset of symptoms. All patients met inclusion
criteria, none met exclusion criteria. Patients with previous
myocardial infarction, previous coronary angioplasty, previ-
ous coronary artery bypass grafting, or heart failure were
excluded to avoid the possible influence of proangiogenic
growth factors released under these conditions. For each
patient, the history of hypertension, diabetes, cigarette
smoking, family history of premature coronary artery dis-
ease, or hypercholesterolemia was elicited. Studied groups
were comparable in terms of epidemiological data (Table 1,
Fig. 1).
Coronary angiography
All patients received a bolus of unfractionated heparin and
dose of aspirin and clopidogrel before invasive procedure.
Coronary angiography, as well as coronary angioplasty with
stent implantation, was performed at admission in every
patient. Coronary angiography and PCI were carried out
via the femoral or radial approach. Standard angiography,
with ≥4 views of the left coronary artery system and 2 views
of the right coronary artery, was preformed and then used
for interpretation.
Laboratory examinations
Troponin I was assessed by a central laboratory using stan-
dardized methods. Blood samples for other laboratory
parameters were collected on admission day and on day 3
of hospitalization. Those blood samples were obtained and
transferred into sterile serum vials and immediately stored
on ice. Within 30 min, samples were centrifuged at 1,000×g
for 15 min and then stored in aliquots of 100 μL at −80 °C.
The serum concentration of EPO and VEGF was measured
by a commercially available and standardized ELISA kit
with a specific monoclonal antibody (Quantikine High Sen-
sitivity, R&D Systems). The assay was performed according
to the manufacturer’s instructions. Two aliquots of each
blood sample were assessed in duplicates simultaneously
in each assay.
Polysomnography
All-night complete polysomnography (Nicolet UltraSom
™) was performed at a reference center for sleep disorders
at Department of Otolaryngology at Czerniakowski Hospital
between 30 and 60 days after the coronary event and then
reviewed by an experienced physician. The study included
analysis of electrocardiography (ECG), electroencephalog-
raphy, electromyography, and electrooculography. Thoracic
and abdominal respiratory movements were recorded by
respiratory inductance plethysmography and arterial oxyhe-
moglobin saturation by oximetry. Nasal and oral airflow
were registered using a thermistor.
Apnea was defined as a cessation of airflow for at
least 10 s, and hypopnea was defined as a 50 % or
greater decrease in the amplitude in either of the two
respiratory effort signals, resulting in a decrease of at
least 4 % in arterial oxyhemoglobin saturation. The
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following polysomnographic parameters were assessed:
Apnea–Hypopnea Index (AHI), mean/minimal oxygen
saturation, minimal desaturation, mean apnea duration,
total sleep duration, and arousal index. Sleep-disordered
breathing was diagnosed when AHI was equal or higher
than five episodes per hour.
Ethics committee
The study protocol was reviewed and approved by the
Ethics Committee of the Medical University of Warsaw
(KB/233/2005), and written informed consent was obtained
from each subject at enrollment.
Table 1 Cardiovascular risk re-
lating to groups (mean; CI)
BMI body mass index, AHI Ap-
nea–Hypopnea Index, LDL low-
density lipoprotein, HDL high-
density lipoprotein, TG trigly-
cerides, RBC red blood cells, Hb
hemoglobin, SB systolic blood
pressure, DBP diastolic blood
pressure, HR heart rate, LVEF
left ventricle ejection fraction
SDB (n=14) (38 %) Non-SDB (n=23) (62 %) p value
AHI≥5 AHI <5
Diabetes mellitus, n (%) 1 (7) 4 (17) 0.63
Arterial hypertension, n (%) 10 (71) 12 (52) 0.31
Dyslipidemia, n (%) 10 (71) 10 (43) 0.17
Smoker, n (%) 11 (78) 19 (82) 0.89
LDL, mg/dL 129.4±23.5 128.6±17.2 0.95
HDL, mg/dL 49.2±6.9 46.1±5 0.45
TG, mg/dL 172.3±68.9 173.3±39.6 0.97
RBC, mln/mm3 4.8±0.2 5.6±1.5 0.41
Hb, g/Dl 14.9±0.5 15.1±0.7 0.71
Age, years 53.3±3.4 50.2±2.4 0.83
Weight, kg 85.4±9.6 84.1±5.4 0.33
Height, cm 174.6±4.7 175.5±2.7 0.4
Hip, cm 102.4±5.6 101.5±3.4 0.73
Waist, cm 102.3±7.6 98.3±4.7 0.71
Neck, cm 41.6±1.4 41.32±1.4 0.24
BMI, kg/m2 27.9±2.8 27.3±1.9 0.62
AHI, events/h 18.7±7.1 1.8±0.6 <0.001
Minimum O2 saturation, % 83.9±4 88.7±1.9 0.04
SBP, mmHg 131.5±18.4 129.4±11.6 0.56
DBP, mmHg 80.2±9.4 75±5.9 0.42
HR, bpm 75.2±7,6 79.7±8 0.40
Killip Class 1.1±0.2 1.2±0.2 0.47
LVEF 49.5±3.4 50.3±2.9 0.77
Fig. 1 SDB and non-SDB
patients according to the in-
farction location. 1 inferion, 2
anterior, 3 anterolateral, 4
inferolateral, 5 lateral, 6
inferoposterior
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Statistical analysis
Patients were divided into two groups according to their
AHI score obtained from the polysomnography. Group 1
was the SDB-positive group with AHI≥5 (n=14, AHI range
5.5–48.7), and group 2 was the SDB-negative group with
AHI<5 (n=23, AHI range 0.0–4.1).
Statistical analysis was performed using the STATIS-
TICA 8.0 software (StatSoft Inc.). The Kolmogorov–
Smirnov test was used for assessing the normality of
the sample distribution.
The continuous variables were tested for the statistically
significant differences using Student’s t test, Mann–Whitney
test or Fisher exact test when appropriate. The differences
between the groups were presented on the box-and-whisker
diagram indicating mean, 95 % confidence interval of the
mean (CI), and range. Spearman rank correlation coeffi-
cients were computed to estimate possible interrelations.
A p value below 0.05was considered statistically significant.
All p values given are two-tailed.
Results
Both admission day and day 3 of hospitalization EPO levels
were statistically significantly different in SDB-positive and
SDB-negative patient groups (p=0.003; p=0.018; Fig. 2).
The SDB-positive group had a higher mean of EPO levels
on both days (day 1 mean, 24.3±7.7; day 3 mean, 21.9±4.0)
compared to the EPO levels in the SDB negative group
(day 1, 10.4±3.2; day 3, 12.5±3.4).
The SDB-positive group had a higher mean of VEGF
levels on both days (day 1 mean, 373.6±222.4; day 3 mean
400.6±248.8) compared to the VEGF levels in the SDB-
negative group (day 1, 310.8±126.3; day 3, 312.9±151.3;
Fig. 3). Mean calculated values were not statistically signif-
icantly different for both measurements (day 1, p=0.98;
day 3, p=0.7).
The maximum Tn levels were also not statistically different
in the patients’ subgroups (56.8±42.8 vs 59.1±27.6; p=0.32).
Moreover, the AHI showed no statistically significant
correlations with EPO, VEGF, and Tn levels. Maximum
Tn and EPO levels showed no correlation.
Discussion
During the past two decades, sleep-disordered breathing
(SDB) has been strongly associated with several cardiovas-
cular disorders. Growing evidence supports the unfavorable
influence of SDB on the cardiovascular system. In particu-
lar, sleep-disordered breathing may deteriorate the course of
hypertension, coronary artery disease, congestive heart fail-
ure, stroke, pulmonary hypertension, and induce arrhyth-
mias [5]. Obstructive sleep apnea increases the risk of
coronary events or death from cardiovascular causes [6].
Cardiovascular disease patients with untreated severe SDB
are also expected to have worse cardiovascular outcomes.
Among patients with coronary artery disease and acute
myocardial infarction, the prevalence of sleep apnea is as
high as 65 % [7, 8].
In a whole body perspective, negative influence of SDB
on the cardiovascular system is a result of hypoxia, sympa-
thetic activation, swings in intrachoracic pressure during
ineffective inspiratory efforts, oxidative stress, and activa-
tion of inflammatory cellular processes as well as increased
glucose intolerance. On the contrary, protective effects of
SDB have also been described. Lavie et al. hypothesized
that nocturnal hypoxemia-reoxygenation cycles may lead to
an ischemic preconditioning conferring profound protection
Fig. 2 EPO levels in SDB and
non-SDB patients on day 1 and
day 3. (mean±SD; 0.95 CI)
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from infarction [9]. Similarly, Koch et al. suggested that
sleep apnea may be neuroprotective [10]. Hypothetically,
the cardioprotection in patients with SDB might be a result
of two different mechanisms. The first hypothesis states that
as a result of repetitive hypoxia the coronary collateral
circulation may be significantly developed. In particular,
Steiner et al. using angiography found that apneic patients
have developed multiple coronary collateral vessels [11].
The second hypothesis states that preconditioning of the
myocardium by recurrent hypoxia may result in specific
metabolic changes in the cardiomyocytes and result in in-
creased hypoxia and acidosis tolerance. Apneic episodes
during sleep may in consequence promote cytokines,
chemokines, and growth factors’ overexpression and
subsequent release into the blood. Among those, it is
EPO and VEGF that are expected to be key players in
pre-conditioning mechanisms responsible for myocyte
survival [12].
The pathophysiological significance of VEGF activation
in SDB is speculative. Some, but not all, investigations have
reported a correlation between the severity of SDB (as
measured by the apnea/hypopnea index) and VEGF levels.
Nevertheless, in multiple reports patients with sleep apnea
have increased serum and plasma levels of VEGF [13–15].
In this paper, the authors found no statistically significant
difference in VEGF levels of SDB-positive and SDB-
negative patients. The authors theorize that this may be
due to the effect of a small sample size (see Fig. 3).
At the same time, conflicting reports on the EPO level in
SDB patients were published. Goldman et al. found no
relation between the degree of hypoxemia and serum EPO
concentrations [16]. On the contrary, Winnicki et al. and Xu
et al. demonstrated that EPO levels in sleep apnea patients
are significantly higher than in normal adults, and that it
may be decreased by successful SDB treatment [17, 18]. It is
therefore hard to speculate on EPO release as a general
phenomenon in SDB patients. Nevertheless, the findings
of this study show that in AMI patients EPO levels on both
days were statistically significantly higher in the SDB-
positive group compared to the SDB-negative group. To
the authors’ best knowledge, there are only three studies
showing endogenous levels of EPO in MI patients.
Namiuchi et al. have shown that in MI patients who
underwent successful primary PCI within 12 h from the
onset of infarction symptoms, high serum EPO level was
associated with a smaller infarct size as determined by the
cumulative creatine kinase (CK) release. Furthermore, a
stepwise multiple regression analysis revealed that the se-
rum EPO level was an independent predictor for the cumu-
lative CK release [19]. This was not confirmed by Ferrario
et al., who observed no correlation between the EPO con-
centration and measured indexes of myocardial damage or
necrosis in patients with AMI [20]. Niccoli et al. have
described that angiographic and ECG no-reflow, in patients
with first ST elevation myocardial infarction undergoing
primary percutaneous coronary intervention, correlated with
lower EPO levels at univariate analysis [21]. In the present
study, there was no correlation between EPO and VEGF
levels and the myocardium necrosis marker Tn.
At this moment, the authors stress that more ques-
tions on MI and OSA codependence remain to be an-
swered in a large population study. Nevertheless, our
research demonstrates that patients with sleep-disordered
breathing tend to have higher EPO levels during acute
myocardial infarction. Also, the levels of VEGF, that
were never studied in such a group of patients [22],
tend to be higher in SDB-positive patients, but the
differences were not statistically significant. This may
suggest a cardioprotective role of sleep apnea during
AMI that takes place through hypoxic preconditioning.
Fig. 3 VEGF levels in SDB
and non-SDB patients on day 1
and day 3 (mean±SD; 0.95 CI)
Sleep Breath (2013) 17:1063–1069 1067
In summary, the authors believe that this work would
further support the hypothesis that SDB, apart from its
negative influence on the cardiovascular system, might
paradoxically trigger some protectivemechanisms. Additional
research on larger groups of patients is necessary to confirm
this hypothesis
Limitations of the study
1. There are several limitations of the study. First of all, the
PSG recordings were carried out 1 to 2 months after the
MI. Therefore, we cannot definitely determine the se-
verity of SDB at the time of MI. Hypothetically, some
patients could have developed the symptoms of conges-
tive heart failure following the infarction, and those
could have affected the diagnosis of SDB. To our best
knowledge, there is only one study showing the fluctu-
ation of SDB severity after acute coronary syndromes
(ACS) [23]. According to Schiza et al., interestingly, the
AHI level is stable during the first month after the ACS
and then decreases over the next 5 months. It seems that
PSG carried at 1–2 months after MI represents SDB that
is not affected additionally by acute heart failure, and
this would be desired by the study design. Moreover, in
our study, patients had the left ventricular ejection frac-
tion examined on the follow-up visit 3 months after the
MI, and none of the patients had a significant decrease
of the LVEF compared to the first measured value. This
enables us to conclude that MI did not significantly
influence the long-term NYHA status of the patients
and SDB severity as a result. It should not be forgotten
that an important limitation of the study by Schiza et al.
is that the authors excluded patients with moderate and
severe SDB as they focused on the sleep architecture.
2. The study is confined to the endogenous EPO levels,
while clinical studies investigate the effect of EPO ana-
logues (i.e., darbepoetin) on LVEF or infarct size [24].
The effect of exogenous EPO administration and
endogenous EPO release cannot be directly compared as
it has been proven that analogues differ according to
receptor binding specificity and binding Km and, finally,
doses administered in trials are not comparable with the
physiological serum EPO levels [25].
3. Another limitation of our study was the serum VEGF
level measurement method. Most authors agree that the
plasma VEGF levels are more stable during measure-
ments and, therefore, should be used [26], but both
serum and plasma levels have been reported in studies
that have been published up until today [27]. In this
project, the serum level measurement was used, but we
believe that it has not influenced the statistical analysis
significantly as the relative levels were compared
between groups, and the absolute values were not consid-
ered. Moreover, the clotting time is the most important
factor influencing VEGF measurement in serum [28]. In
our study protocol, this time interval was constant and no
longer than 30 min. Therefore, it has not substantially
influenced the patient-to-patient comparison.
4. Finally, the number of patients of this pilot study was
too small to analyze the data in more detail and perform
multiple regression analyses. No correlations with both
the AHI or oxygen saturation levels could have been
established, and this may be the result of the small
number of patients enrolled in this pilot study. Therefore,
this and other important questions remain to be answered
in further, larger clinical studies.
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